Hints and tips:
...“Nurtec checked five of six key criteria for Pfizer in picking an asset to acquire, including: high complement to the portfolio, high level of clinical de-risking, high commercial potential, low infrastructure...
...Meanwhile, the outgoing EU ambassador to the UK, João Vale de Almeida, has claimed there is a window to resolve the corrosive post-Brexit dispute as the UK and EU are now “not that far apart”....
...Amid the turmoil, de Bie has kept an eye on the future....
...Letter in response to this article: New body must help make antiviral drug available / From Michel Goldman, President, Institute for Interdisciplinary Innovation in Healthcare, Université libre de Bruxelles...
...“This is a big deal,” said Salomé Cisnal de Ugarte, an antitrust partner at King & Spalding in Brussels....
...But then when he left we had eight years literally of nothing,” Marcus said, faulting the administration of former mayor Bill de Blasio....
...“They have to be de facto regulators of what’s permissible content and what’s not,” he says....
...He added only the “crème de la crème” of funds with strong local knowledge would survive....
...Michael Sklar, develops “nonstandard trial designs”, which seems to basically use maths to speed up the process of developing pharmaceutical studies....
...It’s the sort of message that has become de rigueur since governance put the G in ESG....
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
...James added that the pharmaceutical company’s heavy marketing of opioids was partially motivated by quotas for sales staff....
...It is also used for applications in the marine, medical, military, pharmaceutical, semiconductor and textile industries....
...Halidou Tinto, regional director of the Institut de Recherche en Sciences de la Santé in the Burkina Faso department of Nanoro and the trial’s principal investigator, said he looked forward to demonstrating...
...The UK has played a “fantastic leadership role”, recognising the value of sequencing the Sars-Cov-2 virus, De Souza said. It sequences about 10 per cent of all positive cases....
...The pharmaceuticals groups insist child safety is paramount. Their studies all follow an “age de-escalation, dose escalation” method that gives small amounts to the older participants first....
...Among its allegations, greedy pharmaceutical companies were rushing vaccines to market by cutting corners in clinical trials. Scientists and fact-checkers moved quickly to debunk its theories....
...It was made by US pharmaceutical giant Pfizer and Germany's BioNTech....
...Breathtaking public investment The second trigger was intense and unprecedented investments from public bodies, most notably the US government, which de-risked research and development, according to Mr...
...“Before we pat the drug industry on the back too much, one has to recognise it got involved in this partly because the whole thing has been de-risked by government,” he says....
...The drugmaker said on Wednesday that it was waiving all benefits of the status — which include significant tax incentives and control over prices for at least seven years in a de facto monopoly....
...Gilead Sciences has come under fire for securing a de facto monopoly in the US for an experimental drug seen as a potential coronavirus treatment, with activists accusing the US drugmaker of “morbid calculus...
...Endo International, a pharmaceutical company, fell 9 per cent to $2.65; Teva, the Israeli drugmaker, lost 4.6 per cent to $7.08; and McKesson, another distributor, fell 3 per cent to $142.55 in late-morning...
...Teva Pharmaceuticals, the only remaining manufacturer, fell 1.6 per cent to $7.38, after losing 3.5 per cent during the trading day....
...Mr Michaud, a French regulator who has worked at the Banque de France and the European Central Bank, is the second candidate put forward by the European Banking Authority to become its next executive director...
International Edition